Boehringer Ingelheim Gains Japan MHLW Approval for Nerandomilast in IPF and PPF

Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Boehringer Ingelheim's JASCAYD® (nerandomilast) for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, making Japan the fourth market to clear the compound following the US, China, and the United Arab Emirates. For regulatory affairs leads tracking multi-market dossier sequencing, the approval confirms that the Phase III FIBRONEER™ data package has now satisfied four distinct health authority standards within a compressed submission window.

Nerandomilast is the first phosphodiesterase 4B (PDE4B) inhibitor with both antifibrotic and immunomodulatory effects to receive regulatory clearance in IPF or PPF, and the first new IPF treatment authorised globally in more than a decade. The MHLW decision rests on results from the FIBRONEER™-IPF and FIBRONEER™-ILD Phase III trials, described as the largest Phase III programme conducted across these indications to date. Both trials met their primary endpoints, demonstrating statistically significant reductions in forced vital capacity (FVC) decline versus placebo at week 52. Key secondary endpoints were not met in either trial; however, a pooled analysis reported a nominally significant 59% reduction in risk of death in the nerandomilast 18 mg group without existing treatment compared with placebo.

The Japanese patient context adds a layer of practical relevance for market access and pharmacovigilance planning. An estimated 10,000 to 30,000 patients in Japan are living with IPF, and approximately one-third of those eligible for existing antifibrotic therapies do not receive them, primarily due to gastrointestinal and hepatic tolerability concerns, particularly in older adults. Early discontinuation among those who do initiate treatment is also documented, leaving a measurable gap in sustained therapy coverage. Nerandomilast's tolerability profile, as characterised in the FIBRONEER™ programme, is positioned to address that discontinuation pattern, though post-marketing surveillance under 21 CFR Part 211-equivalent MHLW pharmacovigilance obligations will be required to confirm real-world adherence outcomes.

From a manufacturing and quality standpoint, MHLW approval carries site-specific GMP expectations aligned with ICH Q10 pharmaceutical quality system requirements. Boehringer Ingelheim's ability to secure approvals across four regulatory jurisdictions implies that manufacturing site dossiers, including process validation data and sterility assurance documentation where applicable, have been accepted by the US FDA, China's NMPA, UAE authorities, and now MHLW. QA directors overseeing multi-market supply chains should note that each additional approval jurisdiction typically triggers incremental post-approval change management obligations under the respective national frameworks.

The pace at which Boehringer Ingelheim has progressed nerandomilast across four markets will serve as a reference point for regulatory teams benchmarking multi-regional submission strategies for rare fibrotic disease programmes.

Source: Boehringer Ingelheim via GlobeNewswire, 18 May 2026.